Intraocular lens platform RxSight sets terms for $125 million IPO
RxSight, a commercial-stage provider of post-cataract intraocular lens platform, announced terms for its IPO on Monday.
The Aliso Viejo, CA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed range, RxSight would command a fully diluted market value of $477 million.
RxSight markets its RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, to offers the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
RxSight was founded in 1997 and booked $15 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol RXST. J.P. Morgan, BofA Securities, SVB Leerink, Wells Fargo Securities, and BTIG are the joint bookrunners on the deal. It is expected to price during the week of July 26, 2021.
The article Intraocular lens platform RxSight sets terms for $125 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.